インフュージョンポンプ市場

The secondary research process involved comprehensive analysis of regulatory medical device databases, peer-reviewed clinical engineering journals, healthcare technology publications, and authoritative medical organizations. Key sources included the US Food & Drug Administration (FDA) Center for Devices and Radiological Health (CDRH), FDA MAUDE (Manufacturer and User Facility Device Experience) recall database, European Medicines Agency (EMA), EUDAMED (European Database on Medical Devices), World Health Organization (WHO) Global Health Observatory, Organisation for Economic Co-operation and Development (OECD) Health Statistics, Centers for Medicare & Medicaid Services (CMS) Hospital Outpatient Quality Reporting data, Centers for Disease Control and Prevention (CDC) National Health Statistics Reports, National Institutes of Health (NIH) National Library of Medicine, National Center for Biotechnology Information (NCBI/PubMed) clinical infusion studies, American Society of Health-System Pharmacists (ASHP), Infusion Nurses Society (INS), European Society of Clinical Pharmacy (ESCP), American Association of Diabetes Educators, Oncology Nursing Society (ONS), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), UN Comtrade (HS Code 901890 medical device trade flows), national medical device registries from key markets, and hospital procurement tender databases.

Volumetric pumps, syringe pumps, ambulatory pumps, insulin pumps, PCA pumps, enteral pumps, infusion accessories, adverse event reports, hospital bed-to-pump ratios, clinical safety studies, chronic disease prevalence data, procedure volume metrics, and competitive technology landscape analysis were all gathered from these sources.

To gather both qualitative and quantitative insights, supply-side and demand-side stakeholders were interviewed during the primary research process. CEOs, VPs of R&D, regulatory affairs managers, and commercial directors from infusion pump producers, medical device original equipment manufacturers, and suppliers of infusion consumables were examples of supply-side sources. Biomedical engineering directors, chief pharmacists, infusion nursing specialists, hospital and health system procurement managers, ambulatory surgical center clinical managers, home healthcare coordinators, and medical device purchasing committees from diabetes clinics and oncology centers were among the demand-side sources. Primary research confirmed connected pump and smart pump technology adoption timelines, validated market segmentation across stationary and portable modalities, and collected information on reimbursement coding (HCPCS/CPT), clinical workflow integration, drug library compliance, patient safety protocols, and competitive replacement cycles.

Primary Respondent Breakdown:

By Designation: C-level Primaries (28%), Director Level (35%), Others (37%)

By Region: North America (32%), Europe (30%), Asia-Pacific (28%), Rest of World (10%)

Revenue mapping and installed base analysis were used to get the global market valuation. The following were part of the methodology:

Identification of more than fifty major manufacturers in the device and specialized consumables industries from North America, Europe, Asia-Pacific, and Latin America

Product mapping for insulin pumps, pump accessories (both devoted and non-dedicated), volumetric pumps, syringe pumps, ambulatory pumps, PCA pumps, enteral pumps, and implantable pumps

Examination of the yearly revenues for infusion pump portfolios and related recurring consumables revenue streams, both reported and modeled

coverage of producers who will account for 75–80% of the world market in 2024

Segment-specific valuations for chemotherapy, diabetes management, pain management, pediatrics/neonatology, and gastroenterology applications are derived through extrapolation using top-down (manufacturer revenue validation, trade data analysis) and bottom-up (hospital bed-to-pump ratios × ASP by country, procedure volume × pump utilization rates) approaches.